The Form 4 filing, which reports an insider's stock trades, was submitted on November 18, 2026. Both purchases were dated November 16, 2026.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-16 |
| Buy/Sell | buy |
| Transaction Count | 2 |
| Shares Transacted | 1,750,000 |
| Price | $17.00 |
| Total Transaction Value | $29,750,000.00 |
| Insider | |
| Ticker Symbol | WWB |
| Company | WINDWARD BIO GROUP AG |
| Insider Name | Stampacchia Otello |
| Insider Title | Director |
| Sector - Industry | Other - Unclassified |
| Holdings | |
| Total Shares Owned After Transaction | 875,000 |
| Position Size Change | 200.00% |
| Filing | |
| Filing Date | 2026-11-18 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
Director Otello Stampacchia bought Windward Bio Group AG (WWB) shares in two transactions. The purchases were reported under code P, which identifies a share purchase.
What was the average price of the transaction?
The reported average price was $17.00 per share across the two purchases. Separate prices for each purchase are unavailable.
How did this transaction affect the insider's holdings?
He acquired 1,750,000 shares, while the reported balance afterward was 875,000 shares. The stated 200.00% means the purchased shares equal twice the listed balance of shares owned afterward. The available details do not explain why the purchase total exceeds that balance. Without footnotes or account details to explain the difference, the full change in his holdings remains unclear.
What's the total transaction value?
The total transaction value was $29,750,000.00. That amount covers both purchases reported in the filing.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement. No footnote text was included with the transaction details. That limits what can be said about any other terms or circumstances.
Source: SEC Form 4 filed November 18, 2026.
For research purposes only; not investment advice.